SPECIFIC MONOGRAPHS. A Guide Through The Different Sections. Claude Coune
|
|
|
- Alicia Lawrence
- 5 years ago
- Views:
Transcription
1 SPECIFIC MONOGRAPHS A Guide Through The Different Sections Claude Coune Claude Coune, EDQM, Council of Europe, All rights reserved,
2 Contents of the European Pharmacopoeia: nearly 2100 monographs Claude Coune, EDQM, Council of Europe, All rights reserved, 2010
3 Drug products: specific monographs No monographs on specific preparations, except Vaccines and sera Blood products Radiopharmaceuticals Insulin preparations Claude Coune, EDQM, Council of Europe, All rights reserved,
4 Drug products (2) In the European regulatory situation: Drug product specifications are largely individually tailored Monograph alone often insufficient to ensure quality Exemptions would often be needed (interference from excipients, etc.) Claude Coune, EDQM, Council of Europe, All rights reserved,
5 Specific monographs Requirement for a substance consists of: Specific monograph + general monograph(s) Whole set of requirements define quality Claude Coune, EDQM, Council of Europe, All rights reserved,
6 Claude Coune, EDQM, Council of Europe, All rights reserved,
7 Version date English or French title Latin subtitle Objective : to test impurities, residual solvents and / or related substances Molecular and graphic formulae Relative atomic or molecular mass CAS number Official definition Section for information e.g. appearance, solubility Further information provided on knowledge database (internet) Confirmation of the chemical structure / composition of the product Reference standard available from EDQM Claude Coune, EDQM, Council of Europe, All rights reserved,
8 Reagent described in the EP Recommandations Reference to general chapters List of known and potential impurities When applicable, line in the margin indicating where part of the text has been modified Claude Coune, EDQM, Council of Europe, All rights reserved,
9 TITLE INNs used almost universally (modified to indicate salt) Titles now include degree of hydration Use in labelling required Molecular formula and mass: do not have to be checked! Claude Coune, EDQM, Council of Europe, All rights reserved,
10 DEFINITION Chemical nomenclature Assay limits LC assay: reflect assay variability and purity (eg:, % means 2% assay variability and 3.0% total impurities) Microbiological assay: minimum activity (IU/mg, as is) Biological assay: specific activity (eg: IU/mg) Solvent-free substance is implied even where not stated (see Substances for Pharmaceutical Use, residual solvents) 10 Claude Coune, EDQM, Council of Europe, All rights reserved, 2010
11 SCOPE May include statements on scope (eg route of synthesis) Monograph applies to all grades, unless otherwise stated Special grades may be mentioned in body of monograph (parenteral etc.) Claude Coune, EDQM, Council of Europe, All rights reserved,
12 Use of excipients Definition indicates where applicable that additives can be used (diluents, antioxidants, etc). An active substance is presented with an excipient (antioxidant etc.): does the monograph apply? See Substances for Pharmaceutical Use: Processing with addition of excipients is permitted only where this is specifically stated in the Definition of the individual monograph. Indication on the label Claude Coune, EDQM, Council of Europe, All rights reserved,
13 PRODUCTION SECTION Instructions to manufacturers May relate to source materials, manufacturing process, its validation and control or to inprocess testing Cannot necessarily be verified by independent analyst Compliance established by competent authorities -> e.g. by examination of data or inspection Claude Coune, EDQM, Council of Europe, All rights reserved,
14 PRODUCTION SECTION (2) Development and validation tests (e.g. preservative efficacy, abnormal toxicity) Biologicals: specific activity, if this cannot be checked on the finished product (when the assay of the substance uses a physicochemical method only) Vaccines: often extensive production section Claude Coune, EDQM, Council of Europe, All rights reserved,
15 CHARACTERS Not analytical requirements, do not have to be checked Useful information for the analyst (solubility, hygroscopicity) Polymorphism, where known, is mentioned (see also 5.9 Polymorphism) Physical properties may be mentioned (melting point, refractive index, density) 5.11 Characters section in monographs: methods used for checking by EDQM Claude Coune, EDQM, Council of Europe, All rights reserved,
16 IDENTIFICATION First and Second identifications: defined in General Notices First identification alone is always sufficient, Second is never mandatory Use of Second identification depends on competent authority First identification always has to be carried out at some point (upstream) Claude Coune, EDQM, Council of Europe, All rights reserved,
17 TESTS To detect: organic impurities, inorganic impurities, volatiles Methods: Physical and physico-chemical Chemical Chromatographic Claude Coune, EDQM, Council of Europe, All rights reserved,
18 IMPURITIES CONTROL Adapt to global trade Define practice for future monographs Reflect regulatory practice in monographs Harmonise the approach for different monograph authors Define revision needs Claude Coune, EDQM, Council of Europe, All rights reserved,
19 Basis for monographs SAFETY FIRST! Products of proven safety Products evaluated and approved by competent authorities of Member States Impurity profiles for existing, approved synthetic routes Robust, validated analytical methods based on collaborative laboratory testing 19 Claude Coune, EDQM, Council of Europe, All rights reserved, 2010
20 Basis for impurities control Specifications for approved products and batch analysis data for approved products Specified impurities are those in specifications for approved products Specified impurities are qualified at or above the level indicated in the monograph Claude Coune, EDQM, Council of Europe, All rights reserved,
21 Template for requirements Limits for: Specified impurities Unspecified impurities Total impurities Impurities section Specified impurities Other detectable impurities If the Impurities section is not divided, all the impurities listed are specified Claude Coune, EDQM, Council of Europe, All rights reserved,
22 List of impurities and CRS Specified impurities identified by means of CRS in case of: - specific limit - correction factor to be applied Impurity mix CRS supplied with chromatogram Claude Coune, EDQM, Council of Europe, All rights reserved,
23 Other Detectable Impurities Specific EP category Impurities sections in monographs may have a list of ODIs Analytical information only: the impurity is detected by the monograph method ODIs are limited in the monograph by the limit for unspecified impurities (or Substances for Pharmaceutical Use) Claude Coune, EDQM, Council of Europe, All rights reserved,
24 CF CF Example : Torasemide for system suitability CRS Rs Specified impurities: A, B, C, D. Claude Coune, EDQM, Council of Europe, All rights reserved,
25 Related substances: Example: Amiodarone HCl reversed phase LC elution, UV detection Column: _ size: l =0.15 m, Ø = 4.6 mm _ stationary phase: octadecylsilyl silica gel for chrom. (5µm) _ temperature: 30 C What you will find in the monograph: dimensions, type of stationary phase, particle size. Claude Coune, EDQM, Council of Europe, All rights reserved,
26 Knowledge database Information on - Reference standards - Column or reagent brand names Claude Coune, EDQM, Council of Europe, All rights reserved,
27 IMPURITIES SECTION Gives impurities that are known to be detected by monograph tests Usually controlled by related substances test, but may be other tests Not necessarily exhaustive Based on information obtained and verified during elaboration Claude Coune, EDQM, Council of Europe, All rights reserved,
28 Directive 2003/63/EC However, where a starting material in the European Pharmacopoeia has been prepared by a method liable to leave impurities not controlled in the pharmacopoeia monograph, these impurities and their maximum tolerance limits must be declared and a suitable test procedure must be described. Claude Coune, EDQM, Council of Europe, All rights reserved,
29 Monograph revision Impurities control has to be updated for newly authorised products/sources: [Where] a monograph [may] be insufficient the competent authorities shall inform the European Pharmacopoeia. The marketing authorisation holder shall provide the European Pharmacopoeia with the details of the alleged insufficiency and the additional specifications applied. Claude Coune, EDQM, Council of Europe, All rights reserved,
30 Residual solvents Dealt with in Substances for Pharmaceutical Use and general chapter 5.4 Residual solvents Specific monographs do not include a test for residual solvents, except: Claude Coune, EDQM, Council of Europe, All rights reserved,
31 Residual solvents: Class 1 solvents are always named and limited in monographs Class 3 solvents are only named and limited in monographs when they exceed 0.5% (impact on assay results) Class 2 solvents are NOT named and limited in monographs: chapter 5.4 applies Claude Coune, EDQM, Council of Europe, All rights reserved,
32 ASSAY Well-defined salts: normally only the pharmacologically active part is determined by titration Ph.Eur. policy prefers unspecific but precise assay (titration) provided related substances test is sufficiently characteristic and searching For chromatographic assays chapter defines repeatability requirements Claude Coune, EDQM, Council of Europe, All rights reserved,
33 STORAGE Section is not mandatory Competent authority decides on storage - may decide to make Ph Eur mandatory Product has to be stored so as to ensure compliance with monograph Conventional expressions defined in General Notices Claude Coune, EDQM, Council of Europe, All rights reserved,
34 LABELLING Covered by national and international regulations Ph Eur indicates labelling items needed for application of monographs For example, nominal values (especially excipients) Informational items sometimes included Claude Coune, EDQM, Council of Europe, All rights reserved,
35 LABELLING (2) Labelling is interpreted in broad sense Not just what is read on container Information provided with the product is also included in labelling : package, leaflet, certificate of analysis What appears where is for labelling regulations and regulatory authority Claude Coune, EDQM, Council of Europe, All rights reserved,
36 FUNCTIONALITY-RELATED CHARACTERISTICS (1) New feature of monographs on excipients Section is not mandatory Tests are linked to use (lubricant, tablet compression, etc.) Section provides information on important parameters Claude Coune, EDQM, Council of Europe, All rights reserved,
37 FUNCTIONALITY-RELATED CHARACTERISTICS (2) May include test methods, limits, tolerance on label claim Useful common language for suppliers and users Should lead to better standardisation Information chapter on FRCs (5.15) Claude Coune, EDQM, Council of Europe, All rights reserved,
General concepts in the Ph. Eur.: theory and rationale
General concepts in the Ph. Eur.: theory and rationale General Notices, General Chapters and General Monographs Cathie Vielle Head of European Pharmacopoeia Department The structure of the Ph. Eur. 2 General
Impurity Control in the European Pharmacopoeia
Impurity Control in the European Pharmacopoeia Training Session Zagreb, Croatia, 24-25 May, 2018 Dr Ulrich Rose Head of Division European Pharmacopoeia Department, EDQM Agenda Which impurities are controlled?
The European Pharmacopoeia
The European Pharmacopoeia General methods, Control of impurities, FP monographs, Pharmacopoeial harmonisation International workshop on the Chinese and the European Pharmacopoeias The new editions Dr.
How the European Pharmacopoeia Provides the Framework to Implement QbD Principles
How the European Pharmacopoeia Provides the Framework to Implement QbD Principles Dr Emmanuelle Charton Deputy Head, European Pharmacopoeia Department, EDQM, Council of Europe Structure of the Presentation
European Pharmacopoeia Reference Standards A Lodi, Head of the Laboratory Department, EDQM, Council of Europe
European Pharmacopoeia Reference Standards A Lodi, Head of the Laboratory Department, EDQM, Council of Europe Content Ph. Eur. Reference Standards General notices, terms and definitions Key attributes
Content of the dossier for chemical purity and microbiological quality
Division Certification of Substances CP/CB PUBLIC DOCUMENT (Level 1) English only/anglais seulement PA/PH/ CEP (0) 1 R February 0 Certification of suitability of Monographs of the European Pharmacopoeia
Ph. Eur. monographs and biosimilars
Ph. Eur. monographs and biosimilars Emmanuelle Charton, Ph. D. European Pharmacopoeia Department European Directorate for the Quality of Medicines & HealthCare 1 Place of the Ph. Eur. within the EU regulatory
Guide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia
Guide for the elaboration of monographs on synthetic peptides and recombinant DNA proteins European Pharmacopoeia European Directorate for the Quality of Medicines & HealthCare Edition Council of Europe,
Certification of suitability to the Monographs of the European Pharmacopoeia
AMM/CB PUBLIC DOCUMENT (LEVEL 1) English only/anglais seulement Strasbourg, September 2018 Certification of suitability to the Monographs of the European Pharmacopoeia GUIDELINE ON REQUIREMENTS FOR REVISION/RENEWAL
COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON SUMMARY OF REQUIREMENTS FOR ACTIVE SUBSTANCES IN PART II OF THE DOSSIER
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 28 January 1998 CPMP/QWP/297/97 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE
Identification of the need and uses of a reference standard
Identification of the need and uses of a reference standard Stefan Almeling Deputy Head of Laboratory Department, EDQM, Council of Europe TOPICS General / Definition Role in the monograph How established
A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Pharmaceuticals and cosmetics Final Revision 0 NOTICE TO APPLICANTS A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 This guideline
Consultation by a notified body on an ancillary medicinal substance integrated in a medical device
Consultation by a notified body on an ancillary medicinal substance integrated in a medical device Documentation requirements for an initial consultation Language : French or English Because of the wide
Wirkstoffdokumentation & CEP- Verfahren
Wirkstoffdokumentation & CEP- Verfahren Dr. Wolfgang Herzog AGES PharmMed, Institut Zulassung & Lifecycle Management AGES-Gespräch Am Pulsschlag des Arzneimittelwesens Das Institut LCM 25.11.2010 www.basg.at
Elemental impurities Expectations for APIs and Excipients in the EU
Elemental impurities Expectations for APIs and Excipients in the EU Implementation strategy in the European Pharmacopoeia Dr. Ulrich Rose Head of Division A European Pharmacopoeia Department EDQM 1 Elemental
Proposals for the Guideline on Classification of Variations. Only those variations applicable to the active substance are listed.
December 2008 Proposals for the Guideline on Classification of Variations Only those variations applicable to the active substance are listed. A variation which is not an extension and whose classification
Pharmacopoeial Reference Standards
Pharmacopoeial Reference Standards Industry view point Antony Raj Gomes Head- Quality Management 1 Presentation Overview Indian Industry an update Available guidelines Industry practices Current challenges
VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)
VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) Guideline Title Validation of Analytical Procedures: Methodology Legislative basis Directive 75/318/EEC as amended Date of first adoption December 1996
European Medicines Agency Inspections
European Medicines Agency Inspections London, 31 March 2006 CHMP/QWP/185401/2004 final COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE REQUIREMENTS TO THE CHEMICAL AND PHARMACEUTICAL
Guidelines for Pharmaceutical Equivalence Requirements
Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 1 September 2010 Page 1 of 9 Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 Drug Sector Saudi Food & Drug Authority
11 th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL REFERENCE STANDARDS. Siriphorn Laomanacharoen 21 December 2012
11 th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL REFERENCE STANDARDS Siriphorn Laomanacharoen 21 December 2012 11 th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL REFERENCE STANDARDS Organised by European Directorate
Documentation requirements for an initial consultation
Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,
Implementation of ICH Q3D in the Certification Procedure
LS/CB PUBLIC DOCUMENT (LEVEL 1) PA/PH/CEP (16) 23 Strasbourg, August 2016 Certification of suitability to the Monographs of the European Pharmacopoeia Implementation of ICH Q3D in the Certification Procedure
9/2/2014. USP Monograph Modernization. Todays topics. USP basic. Todays topics. - USP basic. - USP publications. - USP monograph modernization
USP Monograph Modernization Procedure Review and Development Donald Min 2 USP basic Since USP's founding in 1820, our operations have grown exponentially: from 11 volunteers collaborating from their respective
European Regulations for Medicines. Place and Role of the European Pharmacopoeia in Europe Ph. Eur. concept
European Regulations for Medicines Place and Role of the European Pharmacopoeia in Europe Ph. Eur. concept Cathie VIELLE Head of the Ph. Eur. Department, EDQM THE PLACE OF THE PH. EUR. IN EUROPE 2 1 The
Public Assessment Report. Scientific discussion. Progesteron GLF 100 mg and 200 mg soft capsules. (progesterone) NL/H/3415/ /DC
Public Assessment Report Scientific discussion Progesteron GLF 100 mg and 200 mg soft capsules (progesterone) 001-002/DC Date: 6 June 2017 This module reflects the scientific discussion for the approval
European Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
Primary / secondary standards in pharmaceutical QC. Dr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013
Primary / secondary standards in pharmaceutical QC Dr. Christian Zeine LGC Standards GmbH Webinar Series 2013 July 2013 Quick guide to the webinar tools Slide 2 Topics of today s talk Close look on: Main
Annex 1. Good pharmacopoeial practices
Annex 1 Good pharmacopoeial practices 1. Background 68 2. Purpose and scope of good pharmacopoeial practices 69 3. Glossary 69 4. Benefits of good pharmacopoeial practices 70 5. Implementation 70 6. Monograph
The European Approach on Large Sample Sizes in the context of a PAT Environment
The European Approach on Large Sample Sizes in the context of a PAT Environment Dr. Michael Wierer, Deputy Head, European Pharmacopoeia Department, European Directorate for the Quality of Medicines & HealthCare
INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES COMMISSION
EN EN EN INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES COMMISSION Communication from the Commission Guideline on the details of the various categories of variations to the terms of marketing
Public Assessment Report. Scientific discussion. Dalpam 2 mg, 5 mg and 10 mg tablets. (diazepam) NL/H/3588/ /DC
Public Assessment Report Scientific discussion Dalpam 2 mg, 5 mg and 10 mg tablets (diazepam) NL/H/3588/001-003/DC Date: 6 April 2017 This module reflects the scientific discussion for the approval of
Revisions of CEPs. Basic principles for maintaining a CEP
Revisions of CEPs Nimet FILIZ Certification of Substances Department, EDQM Basic principles for maintaining a CEP Any change must be reported to EDQM for approval Original CEP is valid 5 years Holder needs
How to build a good CEP application - ICH Q3D
How to build a good CEP application - ICH Q3D Lisa Moore B.Sc. (Pharm), MPSI Pharmaceutical Assessor, HPRA, Ireland External Expert CEP assessor. The place of the Certification Procedure in the global
VICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit CVMP/VICH/591/98-FINAL London, 10 December 1998 VICH Topic GL2 (Validation: Methodology) Step 7 Consensus
á1225ñ VALIDATION OF COMPENDIAL PROCEDURES
1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst
How to prepare an application for revision of a CEP
How to prepare an application for revision of a CEP P.Poukens-Renwart, PhD Certification of Substances Division EDQM Summary Validity of a CEP Revision background Types of revisions and examples How to
DRUG REGISTRATION REGULATION
DRUG REGISTRATION REGULATION Registration Categories and Application Information Requirements of Chemical Drugs I Registration Categories 1) New chemical entity never marketed in any country. i. Drug substance
English only/anglais seulement PA/PH/CEP (15) 31. Certification of suitability to the Monographs of the European Pharmacopoeia.
MMF/CB PUBLIC DOCUMENT (Level 1) English only/anglais seulement PA/PH/CEP (15) 31 Strasbourg, April 2018 Certification of suitability to the Monographs of the European Pharmacopoeia How to read a CEP Address:
(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION
22.1.2010 Official Journal of the European Union C 17/1 (Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGCIES EUROPEAN COMMISSION Communication from the Commission Guideline
Annex 2: Registration Categories and Application Information Requirements of Chemical Drugs
Annex 2: Registration Categories and Application Information Requirements of Chemical Drugs I Registration Categories 1) New chemical entity never Launched in any country. i. Drug substance and its preparations
GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE IA AND TYPE IB NOTIFICATIONS July 2003
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Final Revision 0 NOTICE TO
Public Assessment Report. Scientific discussion. Kruidvat Paracetamol liquid caps 500 mg, soft capsules. (paracetamol) NL License RVG:
Public Assessment Report Scientific discussion Kruidvat Paracetamol liquid caps 500 mg, soft capsules (paracetamol) NL License RVG: 116359 Date: 10 April 2017 This module reflects the scientific discussion
Reflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances
3 July 2017 EMA/CHMP/CVMP/QWP/826771/2016 Corr. 1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Reflection paper on the requirements for
STANDARD OPERATING PROCEDURES. Handling and working with Analytical Standards
Page: 1 of 6 1.Purpose The purpose of this Standard Operating Procedure is to establish a standardized procedure of using United States Pharmacopoeia (USP) standards, detailing the procedure of qualification,
Impurities from degradation of Drug Substances
Impurities from degradation of Drug Substances REFERENCE 1. ICH - IMPURITIES IN NEW DRUG SUBSTANCES - Q3A(R2) 2. ICH - IMPURITIES IN NEW DRUG PRODUCTS - Q3B(R2) 3. ICH - VALIDATION OF ANALYTICAL PROCEDURES:
General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT
General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (08) 73 R3 QUALIFICATION OF EQUIPMENT CORE DOCUMENT Full document title and reference Document type Qualification of Equipment
Public Assessment Report. Scientific discussion. Pantoprazol SUN Pharma 40 mg, powder for solution for injection. (pantoprazole sodium sequihydrate)
Public Assessment Report Scientific discussion Pantoprazol SUN Pharma 40 mg, powder for solution for injection (pantoprazole sodium sequihydrate) NL/H/3573/001/DC Date: 17 February 2017 This module reflects
ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
Workshop on Skip Testing
12-13 June 2018, Bern, Switzerland Workshop on Skip Testing Rosmarie Neeser Swissmedic, Inspectorates and Licences, Inspector Swissmedic Schweizerisches Heilmittelinstitut Hallerstrasse 7 3000 Bern 9 Schweiz
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
Comments concerning revised texts published in Supplement 9.5
Pharmeuropa Useful information December 2017 1 Comments concerning revised texts published in Supplement 9.5 The following information details the technical modifications that have been made to revised
Medicines Control Authority of Zimbabwe
EFV... QUALITY INFORMATION SUMMARY (QIS) FOREWORD The Quality Information Summary (QIS) template should be completed to provide a condensed summary of the key quality information for product dossiers (PDs)
MODULE 2.3 QUALITY OVERALL SUMMARY PRODUCT DOSSIER (QOS PD)
MODULE 2.3 QUALITY OVERALL SUMMARY PRODUCT DOSSIER () INTRODUCTION The introduction should include proprietary name, non-proprietary name or common name of the drug substance, company name, dosage form(s),
ASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group
ASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group Version Description of Change Author Effective Date v 1.0 Original publication ASMF/DMF WG May 26, 2015 v 1.1 Watermark added ASMF/DMF
1-6 Specifications. Andrew Chemwolo, Technical Officer, WHO Prequalification Team Medicines Assessment
1-6 Specifications Andrew Chemwolo, Technical Officer, WHO Prequalification Team Medicines Assessment Outline Definition Why are specifications important? Setting appropriate specifications PQT-medicines
EDQM Overview of our products and services
ISBN 978-92-871-8127-5 Overview of our products and services Guide to the quality and safety of TISSUES AND CELLS for human application Volume II Pharmacopoeia Volume III Pharmacopoeia Pharmacopoeia 9.09European
Public Assessment Report Scientific discussion. Nystimex (nystatin) SE/H/1366/01/DC
Public Assessment Report Scientific discussion Nystimex (nystatin) SE/H/1366/01/DC This module reflects the scientific discussion for the approval of Nystimex. The procedure was finalised on 2015-01-13.
Guideline on the chemistry of active substances for veterinary medicinal products
9 November 2017 EMA/CVMP/QWP/707366/2017 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on the chemistry of active substances for veterinary medicinal products Draft agreed by Quality
VICH Topic GL10. Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN NEW VETERINARY DRUG SUBSTANCES
European Medicines Agency Veterinary Medicines and Inspections London, 19 February 2007 Doc. Ref.EMEA/CVMP/VICH/837/99-Rev.1 VICH Topic GL10 Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN
GUIDANCE NOTES ON ANALYTICAL METHOD VALIDATION
ON ANALYTICAL METHOD VALIDATION HSA September 2004 Reproduction prohibited for commercial purposes. Reproduction for internal use is authorised, provided the source is acknowledged. MQA Dir: DISK1\GUIDE-MQA-012A-004.doc
Public Assessment Report Scientific discussion. Ebastine Teva (ebastine) SE/H/955/01-02/DC
Public Assessment Report Scientific discussion Ebastine Teva (ebastine) SE/H/955/01-02/DC This module reflects the scientific discussion for the approval of Ebastine Teva. The procedure was finalised at
Writing a Convincing Dossier on Impurities and Method Validation. Dr. Hans Ulrich Gally Swissmedic Swiss Agency for Therapeutic Products
Writing a Convincing Dossier on Impurities and Method Validation Dr. Hans Ulrich Gally Swissmedic Swiss Agency for Therapeutic Products 1 Writing a Convincing Dossier on Impurities and Method Validation
Quality aspects Overview. QP declaration
Quality aspects Overview QP declaration Standards for the quality part of the dossier with focus on: - Materials from animals, nosodes - Proof of microbiological quality, pesticides, heavy metals, organic
Implementation of the ICH Q3D guideline in the Ph. Eur.
Implementation of the ICH Q3D guideline in the Ph. Eur. PQRI/USP Workshop, USP Meeting center 2-3 November 2017 Mr Bruno Spieldenner, European Pharmacopoeia, EDQM Elemental impurities in the Ph. Eur. A
The procedure of Certification of Suitability to the Monographs of the European Pharmacopoeia (CEP) and the EDQM Inspection Programme
18/10/2016 The procedure of Certification of Suitability to the Monographs of the European Pharmacopoeia (CEP) and the EDQM Inspection Programme Chinese & European Pharmacopoeias Workshop 17 October 2016
DACLATASVIR TABLETS (DACLATASVIRI COMPRESSI) Proposal for The International Pharmacopoeia. (May 2018)
May 2018 Draft for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 DACLATASVIR TABLETS (DACLATASVIRI COMPRESSI) Proposal for The International
Public Assessment Report. Scientific discussion. Furosemid Orifarm 40 mg tablets. (Furosemide) DK/H/2430/001/DC. 1 December 2015
Public Assessment Report Scientific discussion Furosemid Orifarm 40 mg tablets (Furosemide) DK/H/2430/001/DC 1 December 2015 This module reflects the scientific discussion for the approval of Furosemid
Adopted by CHMP for release for consultation 15 December Start of public consultation 15 December 2016
1 September 2017 EMA/CHMP/ICH/809509/2016 Committee for Human Medicinal Products ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME. PI July 2018
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 045-1 1 July 2018 GUIDELINES ON THE FORMALISED RISK ASSESSMENT FOR ASCERTAINING THE APPROPRIATE GOOD MANUFACTURING
Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries
Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries IPA / EDQM / WHO Mumbai Conference 28 September 2012 Dr Florence Benoit-Guyod, EDQM Inspector,
Public Assessment Report Scientific discussion. Ebastine Sandoz (ebastine) SE/H/1209/01-02/DC
Public Assessment Report Scientific discussion Ebastine Sandoz (ebastine) SE/H/1209/01-02/DC This module reflects the scientific discussion for the approval of Ebastine Sandoz. The procedure was finalised
EDQM Overview of our products and services
EDQM Overview of our products and services Guide to the Quality and Safety of Organs for Transplantation EDQM 6th Edition 2016 2017 www.edqm.eu www.edqm.eu/store CombiStats : statistical analysis software
Public Assessment Report. Scientific discussion. Methadon HCl Tiofarma 20 mg, 40 mg and 80 mg, tablets. (methadone hydrochloride)
C B G Public Assessment Report Scientific discussion ethadon HCl Tiofarma 20 mg, 40 mg and 80 mg, tablets (methadone hydrochloride) RVG License Number: 117368, 117370-117371 Date: 19 arch 2018 This module
EDQM Conference. The European Pharmacopoeia Is it prepared for the future? Workshop 5. Workshop October 2010 Prague, Czech Republic
EDQM Conference The European Pharmacopoeia Is it prepared for the future? Workshop 5 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Workshop 5 Dr Jean-Louis
Guidance for Industry Q3B(R2) Impurities in New Drug Products
Guidance for Industry Q3B(R2) Impurities in New Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
The European Pharmacopoeia
The European Pharmacopoeia Part 3 Gwenael Cirefice. 1 Agenda Latest news on Water for Injections monograph New General chapters in the field of biologicals (Host Cell Proteins, Raw materials for the production
Variation Regulations (EU)
Variation Regulations (EU) Headlines of the Update APIC c view Hilde Vanneste APIC Task Force leader Hilde.Vanneste@its.jnj.com 1 Content Scope of regulation: Type of procedures and hence 2 strands Current
Guideline on the Requirements for Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials
1 2 3 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the Requirements for Quality Documentation Concerning Biological Investigational
The European Pharmacopoeia & International Harmonisation
The European Pharmacopoeia & International Harmonisation Dr. Claude Coune Head of the Publications & Multimedia Department EDQM, Council of Europe International Harmonisation Increasing exchanges on worldwide
Public Assessment Report Scientific discussion. Lueva (Desogestrel) SE/H/1135/01/DC
Public Assessment Report Scientific discussion Lueva (Desogestrel) SE/H/1135/01/DC This module reflects the scientific discussion for the approval of Lueva. The procedure was finalised at 2012-01-31. For
Public Assessment Report Scientific discussion. Cyklonova Tranexamic acid
Public Assessment Report Scientific discussion Cyklonova Tranexamic acid SE/H/644/01/MR This module reflects the scientific discussion for the approval of Cyklonova 2 x 500 mg film-coated tablets. The
Public Assessment Report Scientific discussion. Emerade (adrenaline tartrate) SE/H/1261/01-03/DC
Public Assessment Report Scientific discussion Emerade (adrenaline tartrate) SE/H/1261/01-03/DC This module reflects the scientific discussion for the approval of Emerade. The procedure was finalised at
Current version 13 October 2016
Implementation Working Group ICH Q11 Guideline: DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL/BIOLOGICAL ENTITIES) and Current version 13 October 2016 In order
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
IMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for
DIDANOSINE ORAL POWDER Final text for addition to The International Pharmacopoeia
Document QAS/06.175(A)FINAL August 2007 DIDANOSINE ORAL POWDER Final text for addition to The International Pharmacopoeia This monograph was adopted at the 41 st WHO Expert Committee on Specifications
Public Assessment Report. Scientific discussion. Lacidipine Double-e Pharma 2 mg, 4 mg and 6 mg film-coated tablets. (lacidipine)
Public Assessment Report Scientific discussion Lacidipine Double-e Pharma 2 mg, 4 mg and 6 mg film-coated tablets (lacidipine) NL/H/2992/001-003/DC Date: 28 July 2016 This module reflects the scientific
REGULATION (EC) No 542/95
REGULATION (EC) No 542/95 Commission Regulation (EC) No 542/95 of 10 March 1995 concerning the examination of variations to the terms of a marketing authorization falling within the scope of Council Regulation
OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT
OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT PA/PH/OMCL (13) 113 2R Evaluation and Reporting of Results Core document Full document title and reference Evaluation and Reporting of Results
Public Assessment Report. Scientific discussion. Pantoprazole ADOH 40 mg, powder for solution for injection. (pantoprazole sodium sesquihydrate)
Public Assessment Report Scientific discussion Pantoprazole ADOH 40 mg, powder for solution for injection (pantoprazole sodium sesquihydrate) NL/H/3656/001/DC Date: 10 April 2017 This module reflects the
CONCEPT PAPER FOR COMMENT
April 2017 Draft document for comment 1 2 3 4 5 6 7 8 CONCEPT PAPER FOR COMMENT TRANSITION FROM MICROBIOLOGICAL TO PHYSICOCHEMICAL ASSAYS IN MONOGRAPHS ON CAPREOMYCIN ACTIVE PHARMACEUTICAL INGREDIENTS
Regulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
Implementation of the ICH Q3D guideline in the Ph. Eur.
Implementation of the ICH Q3D guideline in the Ph. Eur. PQRI/USP Workshop, USP Meeting center 9-10 November 2016 Bruno Spieldenner, Ph. Eur. division, EDQM Elemental impurities in the Ph. Eur. A (r)evolution
OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT
OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT PA/PH/OMCL (05) 48 DEF CORR SCOPE OF ACCREDITATION Full document title and reference Document type Legislative basis Scope of Accreditation
Public Assessment Report Scientific discussion. Nitroglycerin Abcur (glyceryl trinitrate) Asp no:
Public Assessment Report Scientific discussion Nitroglycerin Abcur (glyceryl trinitrate) Asp no: 2013-0647 This module reflects the scientific discussion for the approval of Nitroglycerin Abcur. The procedure
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE
CMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.
CMC Considerations for 505(b)(2) Applications Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011 1 Introduction Outline Brief overview of FDA drug approval pathways
GUIDELINES FOR VARIATION OF REGISTERED MEDICINAL PRODUCTS
GUIDELINES FOR VARIATION OF REGISTERED MEDICINAL PRODUCTS National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda. Tel: +256-0414 - 255665/347391/2 E-mail: